Odyssey Therapeutics, Inc. balance sheet ODTX

As of Sep 30, 2026, Odyssey Therapeutics, Inc. had total assets of $438.1 million and total liabilities of $62.3 million. Stockholders' equity was $375.8 million. It held $387.0 million in cash and investments against $23.5 million of total debt, net cash of $363.5 million. The current ratio, current assets divided by current liabilities, was 12.94.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line
Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Assets
Cash
81
82
36
Short-term investments
245
229
140
Long-term investments
61
122
0
Cash and investments
387
433
176
Receivables
0
0
0
Total current assets
338
321
185
Property and equipment, net
5
5
7
Goodwill
14
14
14
Total assets
438
484
229
Liabilities and equity
Accounts payable
8
8
8
Total current liabilities
26
28
22
Total liabilities
62
63
49
Stockholders' equity
376
421
-524
Debt
Lease liabilities
23
25
26
Total debt
23
25
26
Net cash
364
408
150
Ratios
Current ratio
12.94x
11.36x
8.33x
Debt to equity
0.06x
0.06x
—
Book value per share
7.84
8.80
-211.05
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ODTX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1882782

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.